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Background: Chronic oxidative stress is one of the key mechanisms responsible for disease progression in non-alcoholic
fatty liver disease. However, so far, few studies reported increased circulating levels of oxidative stress markers in
patients with non-alcoholic fatty liver and no study has been performed with newer markers of systemic oxidative
stress. The aim was to assess the relationship between urinary 8-iso-prostaglandin F2α and serum soluble NOX2-derived
peptide and the severity of liver steatosis in subjects with non-alcoholic fatty liver.
Methods: The study was performed in 264 consecutive patients referred for suspected metabolic disease. Steatosis was
defined according to Hamaguchi ultrasonographic criteria. Oxidative stress was assessed by urinary 8-iso- prostaglandin
F2α and serum soluble NOX2-derived peptide levels.
Results: Patients with non-alcoholic fatty liver had higher (p < 0.001) mean values of urinary 8-iso-PGF2α and of serum
soluble NOX2-derived peptide, alanine aminotransferase, Cytokeratin-18 and homeostasis model of insulin resistance
and lower values of serum adiponectin as compared to those without. Prevalence of metabolic syndrome and of its
clinical features was significantly higher in patients with non-alcoholic fatty liver. Same findings were also observed after
the exclusion of obese subjects, or subjects with diabetes or with metabolic syndrome and in those not taking statin
medication. In addition, the levels of urinary 8-iso-PGF2α were independent predictors of non-alcoholic fatty liver and a
strong association of urinary 8-iso-PGF2α and of serum soluble NOX2-derived peptide with the severity of steatosis at
ultrasound was also observed.
Conclusions: We demonstrated increased markers of oxidative stress in subjects with non-alcoholic fatty liver. Urinary
8-iso-PGF2α and serum soluble NOX2-derived peptide levels were independent from obesity, diabetes and metabolic
syndrome and increased with the severity of liver steatosis at ultrasound.
Keywords: Oxidative stress, Non-alcoholic fatty liver, 8-iso-PGF2α, sNOX2-dp, Metabolic syndromeBackground
Nonalcoholic fatty liver disease (NAFLD) includes a wide
spectrum of liver diseases ranging from simple fatty liver
to non-alcoholic steatohepatitis (NASH), which may pro-
gress to fibrosis and even cirrhosis and hepatocellular car-
cinoma [1]. It represents the most common and emerging
chronic liver disease worldwide [2]. NAFLD is strongly* Correspondence: francesco.angelico@uniroma1.it
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reproduction in any medium, provided the orassociated with obesity, insulin resistance, hypertension,
and dyslipidemia, and is now regarded as the liver mani-
festation of the metabolic syndrome (MetS). a cluster of
metabolic and cardiovascular risk factors including sys-
temic inflammation and oxidative stress [3-8].
Traditionally, according to the “two hit” theory, simple
steatosis and NASH have been considered an histological
continuum with increasing degrees of severity [9]. More
recently, the ‘multiple parallel hits’ hypothesis’ has been
proposed, suggesting simple steatosis and NASH as two
unrelated disorders [10,11].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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stress is one of the key mechanisms responsible for liver
damage and disease progression in NAFLD [9]. In par-
ticular, according to the “two-hit” theory, oxidative stress
is a major player triggering the progression of steatosis
to NASH as the result of an imbalance between pro-
oxidant and anti-oxidant chemicals that lead to liver cell
damage. In fact, the increased production of reactive
oxygen species (ROS) is known to cause lipid peroxida-
tion, followed by inflammation, and activation of stellate
cells leading to fibrogenesis. Therefore, although the
mechanisms underlying disease progression remain poorly
understood, a therapeutic strategy targeting oxidative
stress reduction has been proposed and, based on the re-
sults of a single randomized controlled trial [12], supple-
mentation with vitamin E has been suggested by recent
AASLD guidelines for the treatment of NASH in non
diabetic subjects [13].
So far, few studies reported increased circulating levels
of oxidative stress markers in patients with NAFLD
[14-19]. However, most studies contained small number
of patients and no study was able to document the rela-
tionship between the extent of steatosis and systemic
markers of oxidative stress [20]. Larger studies with
newer markers of oxidative stress are required since rou-
tine blood oxidative stress tests are unreliable markers of
hepatic steatosis and probably do not accurately reflect
hepatic oxidative stress. In this study, to assess oxidative
stress in vivo, we measured urinary 8-iso-prostaglandin
F2α (8-iso-PGF2α) and serum levels of soluble NOX2-
derived peptide (sNOX2-dp). Measurement of urinary
8-iso-PGF2α is widely accepted as reliable indicator of
oxidative stress in vivo [21,22]. Soluble NOX2-dp is a
marker of NOX2 activation by blood cells, which is a
member of the NADPH oxidase family which plays an
important role in ROS generation [23,24]. Elevated
urinary 8-iso-PGF2α and serum sNOX2-dp levels have
been described in a number of chronic inflammatory
and metabolic diseases [25-28].
Aim of the present study was to assess the relationship
between urinary 8-iso-PGF2α and serum sNOX2-dp and




The study has been performed in 264 consecutive patients
referred to our metabolic outpatient clinic for suspected
metabolic disease, who had a liver ultrasonographic scan-
ning (US) performed as part of routine clinical examin-
ation. To be eligible for the study, patients had to have
fulfilled the following criteria: no history of current or past
excessive alcohol drinking as defined by an average daily
consumption of alcohol >20 g; negative tests for thepresence of hepatitis B surface antigen and antibody to
hepatitis C virus; absence of history and clinical, biochem-
ical and US findings consistent with cirrhosis and other
chronic liver diseases. None of the subjects were taking
amiodarone and other drugs known to promote fatty liver
disease. Subjects underwent routine clinical and biochem-
ical evaluation. Waist circumference, height and weight
were recorded and body mass index (BMI) was calculated
as weight (Kg) divided by height (m2). Blood pressure was
recorded following standard procedures. Diabetes was
diagnosed according to the WHO criteria [29]. Subjects
taking insulin or oral antidiabetic drugs were considered
to have diabetes. According to the modified criteria of
the ATP III Expert Panel of the US National Cholesterol
Education Program [30], MetS was diagnosed on the
concomitant presence of at least three of the following
five clinical features: waist circumference (central obes-
ity) > 102 cm in men and > 88 cm in women, fasting
blood glucose ≥ 100 mg/dl, triglycerides ≥ 150 mg/dl,
HDL-cholesterol < 40 mg/dl in men and < 50 mg/dl in
women, arterial systolic/diastolic blood pressure ≥130/≥
85 mm/Hg. A metabolic score was calculated for each
patient based on the number of the discrete compo-
nents of MetS identified. Written informed consent was
obtained from all patients before the study. The study
was approved by the ethics committee of the Policlinico
Umberto 1 Hospital of Rome and conforms to the ethical
guidelines of the 1975 Declaration of Helsinki.
Laboratory measurements
A venous blood sample and a spot urine sample were
collected after a 10-14-h overnight fast. Serum total
cholesterol, HDL-cholesterol and triglycerides were
measured by an Olympus AN 560 apparatus using an
enzymatic colorimetric method. LDL-cholesterol levels
were calculated according to the Friedwald formula.
Plasma insulin levels were assayed by commercially
available radioimmunoassay. The homeostasis model of
insulin resistance (HOMA-IR), based on serum fasting
glucose and insulin levels, was used as a measure of
insulin resistance [31]. Urinary 8-iso-prostaglandin F2α
(8-iso-PGF2α), as marker of whole body oxidative stress,
was measured by a previously described and validated
enzyme immunoassay method [32]. Intra-assay and inter-
assay coefficients of variation were 2.1% and 4.5%, respect-
ively. Serum levels of soluble NOX2-derived peptide
(sNOX2-dp) were detected by ELISA method as previ-
ously described [33]; intra-assay and inter-assay coeffi-
cients of variation were 5.2% and 6%, respectively.
Values are expressed as pg/ml. Adiponectin (APN) serum
levels were measured with a commercial immunoassay
(TemaRicerca, Italy). Intra-assay and inter-assay coeffi-
cients of variation were 6 and 8%, respectively. Serum
levels of Cytokeratin 18-M30 (CK-18) were measured as
Table 1 Clinical and biochemical characteristics of






Age (yrs) 54,3 ± 12 56,1 ± 14,4 Ns
Male Gender (%) 64,6 63,3 Ns
BMI (kg/m2) 31,6 ± 5,6 26,8 ± 3,6 <0,001
Urinary 8-iso-PGF2α (pg/mg
creatinine)
714,4 ± 121,5 621,2 ± 125,9 <0,001
sNOX2-dp (pg/ml) 57,4 ± 13.6 47,8 ± 9.9 <0.001
Adiponectin (ng/ml) 8,5 (5/12) 13 (8/15) <0,001
Cytokeratin 18 (mIU/ml) 180 (146/190) 136 (125/173) <0,001
ALT (IU/L) 27,5 (20/40) 18 (14/27) <0,001
HOMA_IR 3,5 (2,4/5,9) 1,9 (1,3/2,3) <0,001
Metabolic syndrome (%)* 67,7 21,7 <0,001
High fasting glucose (%)* 53,8 29,8 < 0,01
Hypertriglyceridemia (%)* 46,9 14,6 <0,001
High waist circumference (%)* 81,9 42,6 <0,001
Low HDL-cholesterol (%)* 37,2 18,8 < 0,05
High blood pressure (%)* 84,5 75,5 Ns
Diabetes (%) 31,1 12,2 < 0,01
Statin use (%) 33,5 42,9 Ns
*According to ATPIII modified criteria (Ref. 30).
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assay (Tema Ricerca, Italy) and expressed as mlU/ml.
Intra-assay and inter-assay coefficients were 6% and 7%
respectively.
Ultrasonographic examination
Liver US scanning was performed to assess the degree of
steatosis. All US were performed by the same operator
who was blinded to laboratory values using an Esaote
Medica apparatus equipped with a convex 3,5 MHz probe.
Liver steatosis was defined according to Hamaguchi cri-
teria based on the presence of abnormally intense, high
level echoes arising from the hepatic parenchyma, liver-
kidney difference in echo amplitude, echo penetration into
deep portion of the liver and clarity of liver blood vessel
structure [34]. Steatosis was assessed semi-quantitatively
on a scale of 0–6: 0, absent; 1,2 mild; 3,4 moderate; 5,6
severe.
Statistical analysis
Statistical analysis was performed by using the SPSS
statistical software version 8.0 for Windows (SPSS, Inc.,
Chicago. Illinois). Student’s t-test for unpaired data was
used for the comparison of mean values. Distribution of
continuous variables was tested for normality using the
a Kolmogorov-Smirnov test. Data are expressed as the
mean ± SD for normally distributed variables and as me-
dian followed by 25th and 75th centiles for non-normally
distributed data. Group comparisons for normally dis-
tributed variables was performed by use of analysis of
variance (ANOVA) and unpaired Student’s t-test when
appropriate, Non normally distributed variables were
tested by Mann–Whitney test and Kruskall-Wallis test.
Proportions and categorical variables were tested by the
χ2 –test and by the 2-tailed Fisher’s exact method when
appropriate. All P values are two-tailed; a P value of less
than 0.05 was considered to indicate statistical signifi-
cance. Multiple linear regression analyses and a stepwise
logistic regression analysis testing for the dichotomous
response variable presence or absence of NAFLD were
performed after controlling for possible clinical and bio-
chemical confounders. The predictor variables entered
in the different regression models were age, gender,
BMI, diabetes, MetS, HOMA-IR, serum triglycerides,
adiponectin, cytokeratin-18, urinary 8-iso-PGF2α and
statin use.
Results
Table 1 reports some clinical and biochemical characteris-
tics of subjects with and without NAFLD. Patients with
NAFLD had significantly higher (p < 0001) mean values of
urinary 8-iso-PGF2α and of serum sNOX2-dp, ALT, CK-
18 and HOMA-IR and lower values of serum adiponectin.Prevalence of MetS and of most of its clinical features was
significantly higher in patients with NAFLD.
Bivariate correlation coefficients between the study
variables are reported in Table 2. A strong positive correl-
ation was found between Urinary 8-iso-PGF2α and serum
sNOX2-dp (r = 0.745; p < 0.001). Both variables were posi-
tively correlated (p < 0.001) with Hamaguchi and MetS
scores, BMI, serum CK-18 and HOMA-IR and negatively
correlated (p < 0.001) with serum adiponectin.
In order to better evaluate the independent effect of
NAFLD on the above variables, separate comparisons be-
tween subjects with and without NAFLD were performed
in subgroups of subjects.
without diabetes, MetS, obesity and statin use (Table 3).
In all subgroups, mean urinary 8-iso-PGF2α and serum
sNOX2-dp were significantly higher in subjects with
NAFLD, as compared with those without NAFLD. More-
over, most of the other differences were still statistically
significant when comparisons were performed in subjects
without diabetes, without obesity, without MetS and in
those not taking statins. Prevalence of NAFLD and of se-
vere steatosis significantly increased in the increasing ter-
tiles of urinary 8-iso-PGF2α (66.3 vs 83.7 vs 91.9; p < 0.001
and 13.8 vs 30.3 vs 45.6: p < 0.001, respectively).
Table 4 reports mean values of some biochemical vari-
ables according to NAFLD severity at ultrasound exam-
ination. A progressive, statistically significant increase
(p < .001) of mean values of urinary 8-iso-PGF2α and
Table 2 Linear correlation coefficients between some clinical and biochemical variables
PGF2α
Urinary 8-iso-PGF2α (pg/mg creatinine) 1 BMI
Body mass index (kg/m2) ,803** 1 Age
Age (yrs) -,051 -,089 1 Adipo
Adiponectin (ng/mL) -,686** -,838** ,004 1 CK-18
Cytokeratin-18 (mIU/ml) ,684** ,723** ,011 -,602** 1 NOX2
sNOX2-dp (pg/ml) ,745** ,570** -,074 -,430** ,491** 1 ALT
ALT (IU/L) ,002 ,017 -,098 ,031 ,061 -,007 1 HOMA-IR
HOMA-IR ,321** ,417** ,063 -299** ,354** ,288** ,254** 1 MetS code
MetS code§ ,390** ,468** ,191** -,405** ,436** ,351** ,143* ,536** 1
Hamaguchi score^ ,374** ,477** ,012 -,369** ,339** ,325** ,416** ,497** ,481**
*p < .01; **p < .001; §no. of variables of MetS according to ATPIII modified criteria (Ref. 30); ^see Methods.
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transpeptidase (GGT) and HOMA-IR was observed
from the group without fatty liver to the groups with
mild, moderate and severe steatosis, while a decreasing
trend was observed for serum adiponectin.
Since urinary 8-iso-PGF2α and serum sNOX2-dp values
were also significantly correlated with HOMA-IR and
MetS score, a separate analysis was performed in patients
with MetS. Also in this clinical setting, an increasing trend
of the mean levels of both urinary 8-iso-PGF2α and serum
sNOX2-dp with increasing NAFLD severity was observed.
Table 5 reports the results of the stepwise multiple logis-
tic regression analysis performed to assess the independ-
ent contribution of urinary 8-iso-PGF2α for the prediction
of NAFLD. Age, urinary 8-iso-PGF2α and MetS were in-
dependent predictors of NAFLD, after controlling for gen-
der, BMI, HOMA-IR, serum triglycerides and adiponectin,
diabetes and statin use.
Two more regression analyses were performed to
evaluate factors independently related to the severity of
the NAFLD (serum cytokeratin-18 levels) and factors in-
dependently related to the degree of systemic oxidative
stress (urinary 8-iso-PGF2α).
In the first multiple linear regression analysis, BMI
(standardized coefficient β = 0. 236; SE = 0.725; p = 0.019),
urinary 8-iso-PGF2α (standardized coefficient β = 0.268;
SE = 0.029; p = 0.002) and serum adiponectin (standard-
ized coefficient β = −0.193; SE = 0.726; p = 0.012) were
independent predictors of serum CK-18 levels (R2 = 0.39).
In the second regression analysis, BMI (standardized
coefficient β = 0.687; SE = 1.430; p = 0.000) and serum
cytokeratin-18 (standardized coefficient β = 2.904; SE =
0.144; p = 0.004) were independently associated with
urinary 8-iso-PGF2α levels (R2 = 0.66).
Discussion
Our findings show, for the first time, an increased sys-
temic oxidative stress in subjects with NAFLD, as assessedby increased levels of urinary 8-iso-PGF2α, currently
regarded as the best measure of oxidative stress in vivo
and of serum sNOX2-dp, a marker of NOX2 activation
by blood cells, which plays an important role in ROS
production [21-23].
So far, few studies have investigated markers of sys-
temic oxidative stress in subjects with NAFLD. However,
no study has documented the relationship between urin-
ary 8-iso PGF2α and serum sNOX2-dp and the extent of
fatty liver. In a small study performed in 21 subjects
with NASH and 19 controls, subjects with NASH had
significantly higher levels of oxidized LDL and of thio-
barbituric acid-reacting substances (TBARS) suggesting
an increased cardiovascular risk [14]. Similar results
were reported in India, where TBARS levels were signifi-
cantly elevated and GSH/GSSG ratio was significantly
decreased in NAFLD subjects without and with type 2
diabetes [14]. Increased systemic levels of malondialde-
hyde were observed in 58 male patients with histologi-
cally proven NAFLD compared to healthy age matched
males [15]. In a further study, NAFLD children with im-
mune responses against MDA derived antigens showed
more severe lobular inflammation and had a 13-fold
higher prevalence of overt NASH suggesting the pres-
ence of oxidative stress in a high proportion of NAFLD
children [17]. In two more study the percentage of hepato-
cytes positive for 8-OHdG expression and serum 8-OHdG
levels were significantly higher in patients with NASH
than simple fatty liver, while the oxidative stress marker
GGT was increased in both conditions [18,35,36]. Finally,
in a recent cross-sectional study, oxidative stress detected
as the ratio of plasma total antioxidant status to total oxi-
dant status was associated with insulin resistance in obese
adolescents with NAFLD [19].
Our study was carried out in a large sample of con-
secutive patients referred for suspected metabolic dis-
ease, who had a liver US performed as part of routine
clinical examination. We found statistically significant
Table 3 Clinical and biochemical characteristics in subjects without diabetes, or obesity or metabolic syndrome and in statin non users according to the
presence or absence of NAFLD
Subjects w/o diabetes Subjects w/o obesity^ Subjects w/o MetS Subjects w/o statin use
Nafld (144) no-Nafld (43) Nafld (85) no-Nafld (39) Nafld (73) no-Nafld (41) Nafld (139) no-Nafld (28)
Age (yrs) 52,1 ± 12,7 54,4 ± 14 55,0 ± 13,0 55,0 ± 14,7 50,1 ± 13,1 54,7 ± 13,0 50,8 ± 11,8 53,0 ± 15,9
Male gender (%) 33,3 34,9 23,8 34,2 31,8 30,6 36,0 39,3
BMI 30,9 ± 5,6 26,9 ± 3,7 *** 26,6 ± 2,3 25,2 ± 2,0*** 29,5 ± 5,7 26,5 ± 3,5** 31,0 ± 5,8 27,2 ± 3,9***
Urinary 8-iso-PGF2α (pg/mg creatinine) 703,4 ± 117,9 634,1 ± 106,7*** 626,6 ± 81,5 583,6 ± 102,7* 672,1 ± 123,0 619,3 ± 95,1* 711,6 ± 133 627,5 ± 147,9**
sNOX2-dp (pg/ml) 56,4 ± 13,8 49,9 ± 8,9*** 49,4 ± 12,9 45,8 ± 8,9 54,0 ± 13,3 48,4 ± 8,3* 57,5 ± 14,1 47,5 ± 10,7***
Adiponectin (ng/ml) 8,5 (5,5/12) 13,5 (7,5/15)*** 12,5 (10,5/14) 13,5 (12,5/14,5)** 10,5 (6,2/13,6) 13,0 (6,5/14)* 7,5 (5/11,5) 13,5 (6,8/15)***
Cytokeratin-18 (mIU/ml) 174,5 (136/189) 130,0 (125/175)** 149,0 (125/179) 126,0 (110/165)* 161,5 (125/180 165,0 (125/178) 179,0 (145/190) 140,0 (125/179)**
ALT (IU/L) 26 (20/40) 20 (15/27)*** 34 (23/42) 15 (13/24)*** 26 (19/27) 18 (14/27)** 27 (20/40) 18 (14/27)***
GGT (IU/L) 25 (17/40)* 20 (14/28) 30 (20/52) 21 (16/23)** 23 (16/10) 21 (18/36) 25 (17/44)* 21 (13/30)
HOMA_IR 2,9 (2,1/4,5) 1,8 (1,2/2,1)*** 2,8 (1,8/4,3) 2,0 (1,6/3,2) 2,6 (1,7/3,4) 1,8 (1,5/2,1)* 3,1 (2,2/5,5) 1,8 (1,1/2,1)***
MetS§ (%) 57,0 12,5*** 51,8 19,4*** 0 0 57,8 16,0***
High Fasting Glucose§ (%) 32,9 19,5 44,0 30,6 15,2 13,9 41,3 23,1
High Triglycerides§ (%) 44,8 11,9*** 39,3 16,2* 7,6 13,9 40,9 11,1**
High Waist Circumference§ (%) 78,2 43,9*** 55,4 27,0** 59,1 38,9 80 46,2***
Low C-HDL§ (%) 35,7 16,7* 31,0 21,6 6,1 13,9 37,2 14,8*
High Blood Pressure§ (%) 79,0 74,4 81,0 73,7 69,7 75,0 80,3 75,0
Diabetes (%) 0 0 21,4 15,8 7,6 2,8 20,1 7,1
Statin use (%) 22,9 39,5* 31,0 47,4 13,6 41,7** 0 0



















Table 4 Some biochemical variables in all subjects and in subjects with MetS according to NAFLD severity at
ultrasound examination
ALL SUBJECTS SUBJECTS WITH MetS












































8,8 (6,0/13,5) 6,0 (4,9/9,0) <,001
12,5
(5,0/13,9)





















ALT (IU/L) 18 (14/27) 21 (17/34) 26 (19/36) 34 (25/45) <,001 16 (12,/22) 26 (19/37) 25,5 (17/36,3) 32 (24/43) <,001
GGT (IU/L)
21 (14/30,5) 23 (16/40,7) 21 (16/35)
33,50
(24/61)
<,001 14 (11/25) 25 (19/42) 22 (16/34) 34 (24/64) <,001
HOMA_IR 1,9 (1,3/2,3) 2,5 (1,7/3,8) 3,3 (2,2/5,4) 5,2 (3,1/7,3) <,001 2,9 (1,1/3,8) 2,9 (1,7/4,5) 3,9 (2,9/5,9) 5,6 (3,3/7,4) <,001
Metabolic
syndrome (%)*
21,7 50,0 63,5 81,8 <,001 100 100 100 100 -
*Defined according to ATPIII modified criteria (Ref. 30).
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in subjects with fatty liver, as compared to those without.
The same findings were also observed after the exclusion
of obese subjects, or subjects with diabetes or with MetS
and in those not taking statin medication. In addition,
the levels of urinary 8-iso-PGF2α were independent
predictors of NAFLD and a strong association of urinary
8-iso-PGF2α and of serum sNOX2-dp with the severity
of liver steatosis at ultrasound examination was also
observed. In our study, a correlation was also found be-
tween HOMA-IR, urinary 8-iso PGF2α and sNOX2-dp,
confirming the interdependency of insulin resistance and
oxidative stress in the pathogenesis of NAFLD. Moreover,
urinary 8-iso-PGF2α were also independent predictors
of serum CK-18, a marker of apoptosis reflecting liver
disease severity, further suggesting a possible role of
oxidative stress in the progression from simple fatty
liver to NASH [37].
Our results support the hypothesis that NAFLD is as-
sociated to enhanced oxidative stress as the result of
increased 8-isoprostane production induced by NOX2
activation. Although the association between NAFLD and
markers of increased oxidative stress does not necessary
imply causality, our findings suggest oxidative stress as aTable 5 Stepwise multiple logistic analysis of independent pr
B S.E.
Age (yrs) -,048 ,021
Urinary 8-isoprostanes (pg/mg creatinine) ,006 ,002
Metabolic syndrome 1,533 ,535
Variables entered on step 1: age, gender, BMI, HOMA-IR, serum triglycerides and adpossible target of antioxidant therapy in patients with
NAFLD and give support to the indication for vitamin E
supplementation for non diabetic, non cirrhotic patients
with NASH [12,13].
Measurement of 8-iso-PGF2α has overcome many of
the limitations associated with other methods and has
emerged as the most reliable approach to assess the role
of in vivo oxidative stress status in the pathogenesis of
human disease. Isoprostanes are stable prostaglandin-
like compounds that are produced by free radical medi-
ated lipid peroxidation in vivo are as a result of oxidative
damage to cell membranes. They are unaffected by dietary
lipid composition and are increased in animal models
of oxidant injury. Based on these characteristics, F2-
isoprostanes have emerged as the gold standard of oxi-
dative stress in vivo, especially if determined in urine
[22,23]. In fact, measurement of urinary 8-iso-PGF2α
has several advantages such as non invasiveness, stabil-
ity and absence of any significant daily and day-to-day
variability. We have previously demonstrated increased
urinary 8-iso PGF2α values also in other chronic condi-
tions such as hypercholesterolemia, metabolic syndrome,
obstructive sleep apnoea syndrome and peripheral artery
disease [25-28]. Recently, women with high levels ofedictors of NAFLD in 264 subjects
P O.R. 95,0% C.I. for O.R.
Lower Upper
,021 ,953 ,915 ,993
,003 1,006 1,002 1,010
,004 4,634 1,622 13,236
iponectin, urinary 8-isoprostanes, metabolic syndrome, diabetes, statin use.
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http://www.biomedcentral.com/1471-230X/14/81urinary 8-iso PGF2α were reported to have an 80% in-
creased risk of dying of coronary heart disease or stroke,
supporting the involvement of oxidative stress also in the
pathophysiology of cardiovascular disease [36]. In our
study, cytokeratin-18, a marker of liver disease severity,
was an independent predictor of urinary 8-iso PGF2α,
thus suggesting also a possible effect of fatty liver on
systemic oxidative stress.
Our study may have some limitations. First, we de-
tected fatty liver by ultrasound, which is a qualitative
method inadequate to quantify less than 20% liver fat
content [38]. Moreover, the Hamaguchi ultrasonographic
score does not specifically predict NASH. The gold
standard for the diagnosis of NASH is liver biopsy, but
this is an invasive procedure with potentially serious
complications and is therefore not acceptable without
clinical indication. We acknowledge that grades of stea-
tosis could have been better determined by magnetic
resonance spectroscopy. However, Hamaguchi score
showed 100% specificity and 91.7% sensitivity when
compared with liver biopsy in NAFLD patients [34].
Second, although performed in a large series of patients,
the study has been carried out in patients recruited in a
Hospital-based setting. Finally, this is a cross-sectional
study and it is therefore impossible to say whether oxi-
dative stress, caused by obesity, contributes to the
pathophysiology of NAFLD (or perhaps more NASH) or
whether the inflamed liver contributes to the systemic
oxidative stress.
Conclusion
We demonstrated increased markers of oxidative stress
in subjects with NAFLD. Urinary 8-iso-PGF2α and
serum soluble NOX2-derived peptide levels were inde-
pendent from obesity, diabetes and MetS and increased
with the severity of liver steatosis at ultrasound. Our
findings are consistent with the “two-hit” theory based
on the prominent role of oxidative stress as a major
player triggering the progression of steatosis to NASH.
Moreover, they are also in agreement with the more re-
cent “multiple parallel hits” theory including genetic pre-
disposition, intestinal macrobiota and insulin resistance
as the major contributors of increased oxidative stress
and progressive liver damage [10]. Finally, they may also
give support to the recommendation for early antioxi-
dant treatment extended even to subjects with simple
steatosis.
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